Court Finds Corcept Therapeutics’ Patents Not Infringed
January 02, 2024 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
November 01, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Appoints Monica Tellado as President, Emerging Markets
November 01, 2023 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)
October 26, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 25, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update...
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
August 02, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 26, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update...
Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
July 17, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
Phase 1b study demonstrates that miricorilant, a selective cortisol modulator, effectively reduces liver fat, improves liver health and key metabolic and lipid measures and is well-toleratedCorcept...
Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer
June 27, 2023 08:00 ET
|
Corcept Therapeutics Incorporated
Relacorilant plus nab-paclitaxel improved progression-free survival (PFS), duration of response (DoR) and overall survival (OS), without increasing side effects, compared to nab-paclitaxel...
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
May 03, 2023 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...